FRIDAY, Aug. 19 (HealthDay News) -- Testosterone replacement therapy (TRT) with Testim (testosterone 1 percent) topical gel for 12 months significantly increases total testosterone (TT), free testosterone (FT), and total brief male sexual function inventory (BMSFI) score in men with hypogonadism, according to a study published online Aug. 11 in The Journal of Sexual Medicine.
Mohit Khera, M.D., M.B.A., M.P.H., from the Baylor College of Medicine in Houston, and colleagues examined whether a 12-month treatment regimen with testosterone gel improves sexual function in men with hypogonadism and in subgroups defined by low testosterone, phosphodiesterase type 5 inhibitor use, and prior TRT. Improvement in sexual function was measured by the BMSFI. A total of 271 men with hypogonadism, whose baseline testosterone and BMSFI measurements were available, were selected from the Testim Registry in the United States (TRiUS), treated with Testim topical gel, and followed for 12 months. Measurement of TT, FT, and BMSFI, and physical exam and body measurements were the main outcome measures at one, three, six, and 12 months.
The investigators found that, compared to baseline, a significant increase occurred in average TT and FT levels at 12 months of TRT. At 12 months, there was a significant increase in mean total BMSFI score from baseline, and at each visit the mean total BMSFI score significantly increased from baseline, overall and in all subgroups, in all domains (sex drive/libido, erectile function, ejaculatory function, level of bother). Regression analysis revealed significant association between increased total BMSFI score and increased TT levels at six months.
"In hypogonadal patients, 12-month administration of topical testosterone gel resulted in increased TT and FT levels and significantly improved sexual function," the authors write.
All of the study authors disclosed financial ties to the pharmaceutical industry, including Auxilium Pharmaceuticals, which funded the TRiUS registry, which partially funded the study.
Copyright © 2011 HealthDay. All rights reserved.
|Previous: Donor-Specific Antibody Tied to Renal Graft Rejection Risk||Next: Sarcoma Characteristics ID'd in TP53 Mutation Carriers|
Reader comments on this article are listed below. Review our comments policy.